Loading stock data…
IOVA
$3.88-0.12 (-3.00%)
After Hours$3.88+0.00 (+0.04%)· Last close Jun 9
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Iovance Biotherapeutics, Inc. in the Healthcare sector is trading at $3.88. Wall Street consensus targets $8.80 (10 analysts), implying a +126.8% move over the next 12 months. The stock is currently 31% below its 52-week high of $5.63, remaining 33.3% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +126.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$3.88
Potential Downside
0%
Whystock Fair Value$3.88
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Buy
Mean target$8.80+126.8%
Range$4.00 – $14.00
Fundamentals
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the Unite...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.03%
Volume
Today's trading volume
11.19M
Recent News
Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the top penny stocks to buy in investors’ stock portfolio. On June 1, research firm Citizens reiterated a Market Outperform rating on Iovanace Biotherapeutics (NASDAQ:IOVA) with a $5 price target. The research firm remains confident about the company’s outlook, impressed by the real-world presentation at ASCO that broadened […]
A Look At Iovance Biotherapeutics (IOVA) Valuation After Australian Conditional Approval For Amtagvi
Iovance Biotherapeutics (IOVA) is back in focus after Australia’s Therapeutic Goods Administration granted conditional approval for Amtagvi, a tumor infiltrating lymphocyte therapy for previously treated unresectable or metastatic melanoma in a high incidence market. See our latest analysis for Iovance Biotherapeutics. The TGA decision comes after a volatile period, with the stock delivering a 67.86% year to date share price return and a 106.34% total shareholder return over one year...
Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Small-Cap Stocks to Buy Now?
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 8, Chardan reiterated Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) as a Buy but lowered its price target of the stock to $14 from $16. The price target cut is in response to Amtagvi’s launch guidance. The company delivered […]
Iovance Biotherapeutics (IOVA) Gets Australia Nod for Amtagvi, Climbs 15%
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the 9 Stocks Crushing the Market With Surging Returns. Iovance Biotherapeutics climbed by 15.57 percent on Thursday to end at $4.38 apiece after securing the conditional approval of Australia’s Therapeutic Goods Administration (TGA) for the treatment of melanoma through its therapy, Amtagvi. The approval marked Iovance Biotherapeutics Inc.’s (NASDAQ:IOVA) […]
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?
Tread carefully, but certain factors make this speculative biotech play stand out.